These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10737724)

  • 1. Suppressive effects of dominant negative ras mutant N116Y on transformed phenotypes of human bladder cancer cells.
    Watanabe T; Shinohara N; Sazawa A; Kobayashi Y; Ogiso Y; Kimura T; Takiguchi M; Yasuda J; Hashimoto A; Koyanagi T; Kuzumaki N
    Cancer Lett; 2000 Feb; 149(1-2):195-202. PubMed ID: 10737724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenovirus-mediated gene therapy for bladder cancer in an orthotopic model using a dominant negative H-ras mutant.
    Watanabe T; Shinohara N; Sazawa A; Takimoto M; Hashimoto A; Koyanagi T; Kuzumaki N
    Int J Cancer; 2001 Jun; 92(5):712-7. PubMed ID: 11340577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inhibition of ras-dependent transformation by using dominant negative ras mutant N116Y].
    Yokoyama T
    Hokkaido Igaku Zasshi; 1995 May; 70(3):459-71. PubMed ID: 7590597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of various human tumor cell lines by a dominant negative H-ras mutant.
    Ogiso Y; Sakai N; Watari H; Yokoyama T; Kuzumaki N
    Gene Ther; 1994 Nov; 1(6):403-7. PubMed ID: 7584106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppressive effect of modified dominant negative RAS mutant on human cancer by gene transfer with non-viral vector.
    Suzuki H; Kuzumaki S; Nakagawa K; Takimoto M; Shichinohe T
    Cancer Biol Ther; 2006 Nov; 5(11):1487-91. PubMed ID: 17102594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y.
    Shichinohe T; Senmaru N; Furuuchi K; Ogiso Y; Ishikura H; Yoshiki T; Takahashi T; Kato H; Kuzumaki N
    J Surg Res; 1996 Dec; 66(2):125-30. PubMed ID: 9024823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y.
    Senmaru N; Shichinohe T; Takeuchi M; Miyamoto M; Sazawa A; Ogiso Y; Takahashi T; Okushiba S; Takimoto M; Kato H; Kuzumaki N
    Int J Cancer; 1998 Oct; 78(3):366-71. PubMed ID: 9766573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice.
    Takeuchi M; Shichinohe T; Senmaru N; Miyamoto M; Fujita H; Takimoto M; Kondo S; Katoh H; Kuzumaki N
    Gene Ther; 2000 Mar; 7(6):518-26. PubMed ID: 10757026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dominant role for the c-Jun NH2-terminal kinase in oncogenic ras-induced morphologic transformation of human lung carcinoma cells.
    Xiao L; Lang W
    Cancer Res; 2000 Jan; 60(2):400-8. PubMed ID: 10667594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible regulation of the transformed phenotype of ornithine decarboxylase- and ras-overexpressing cells by dominant-negative mutants of c-Jun.
    Kielosto M; Nummela P; Katainen R; Leaner V; Birrer MJ; Hölttä E
    Cancer Res; 2004 Jun; 64(11):3772-9. PubMed ID: 15172983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutive overexpression of a 89 kDa heat shock protein gene in the HBL100 human mammary cell line converted to a tumorigenic phenotype by the EJ/T24 Harvey-ras oncogene.
    Lebeau J; Le Chalony C; Prosperi MT; Goubin G
    Oncogene; 1991 Jul; 6(7):1125-32. PubMed ID: 1861862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoplastic progression by EJ/ras at different steps of transformation in vitro of human uroepithelial cells.
    Pratt CI; Kao CH; Wu SQ; Gilchrist KW; Oyasu R; Reznikoff CA
    Cancer Res; 1992 Feb; 52(3):688-95. PubMed ID: 1310069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retroviral gene transfer of dominant negative raf-1 mutants suppresses ha-ras-induced transformation and delays tumor formation.
    Heinicke T; Radziwill G; Nawrath M; Rommel C; Pavlovic J; Moelling K
    Cancer Gene Ther; 2000 May; 7(5):697-706. PubMed ID: 10830717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flat revertants of EJ human bladder carcinoma cells show two different mechanisms of reversion.
    Paterson H; Mbamalu G; Marshall CJ
    Ciba Found Symp; 1989; 142():134-43; discussion 143-8. PubMed ID: 2663383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human retinoblastoma gene product prevents c-Ha-ras oncogene mediated cellular transformation of mouse fibroblasts.
    Kivinen L; Pitkänen K; Laiho M
    Oncogene; 1993 Oct; 8(10):2703-11. PubMed ID: 8378082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of tumorigenicity in Ras-transformed fibroblasts by alpha 2(I) collagen.
    Travers H; French NS; Norton JD
    Cell Growth Differ; 1996 Oct; 7(10):1353-60. PubMed ID: 8891339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated Ki-Ras suppresses 12-O-tetradecanoylphorbol-13-acetate-induced activation of the c-Jun NH2-terminal kinase pathway in human colon cancer cells.
    Okumura K; Shirasawa S; Nishioka M; Sasazuki T
    Cancer Res; 1999 May; 59(10):2445-50. PubMed ID: 10344756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of malignant growth potentials of v-Src-transformed human gallbladder epithelial cells by adenovirus-mediated dominant negative H-Ras.
    Tokumitsu Y; Nakano S; Ueno H; Niho Y
    J Cell Physiol; 2000 May; 183(2):221-7. PubMed ID: 10737897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tropomyosin-2 cDNA lacking the 3' untranslated region riboregulator induces growth inhibition of v-Ki-ras-transformed fibroblasts.
    Janssen RA; Mier JW
    Mol Biol Cell; 1997 May; 8(5):897-908. PubMed ID: 9168473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme.
    Funato T; Shitara T; Tone T; Jiao L; Kashani-Sabet M; Scanlon KJ
    Biochem Pharmacol; 1994 Oct; 48(7):1471-5. PubMed ID: 7945447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.